

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-18. (canceled)

19. (original) A tablet comprising: a) a pharmaceutically active ingredient, b) dextrose monohydrate, and c) crospovidone.

20. (original) The tablet of claim 19 having a hardness of less than about 15 kp/cm².

21-23 (canceled)

24. (previously presented) A process for preparing a chewable or disintegrative tablet, comprising forming a tablet having a friability of less than about 2% from a mixture comprising a pharmaceutically active ingredient, an excipient in the form of a hydrate, and a water-swellable excipient, and then applying sufficient heat to the tablet for a sufficient time to decrease the hardness of the tablet by at least about 20%.

25. (amended) The process of claim 24, wherein the tablet is formed by direct compression.

26. (amended) The process of claim 24 wherein the tablet has a final hardness of less than about 15 kp/cm².

27. (amended) The process of claim 24, wherein the friability is less than about 1% and the tablet has a final hardness in the range of about 1-8 kp/cm².

28. (amended) The process of claim 24, wherein prior to application of heat to the tablet, the tablet is packaged.

29. (amended) The process of claim 21_24, wherein the active ingredient is selected from the group consisting of acetaminophen, ibuprofen, pseudoephedrine, dextromethorphan, diphenhydramine, chlorpheniramine, calcium carbonate, magnesium hydroxide, magnesium carbonate, magnesium oxide, aluminum hydroxide, mixtures thereof, and pharmaceutically acceptable salts thereof.

30. (amended) The process of claim 21_24, wherein the excipient in the form of a hydrate is selected from the group consisting of dextrose monohydrate, maltodextrin, lactose monohydrate, dextrin, citric acid monohydrate, dibasic calcium phosphate dihydrate, dibasic sodium phosphate dihydrate, dibasic sodium phosphate heptahydrate, dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate monohydrate, and monobasic sodium phosphate dihydrate.

31. (amended) The process of claim 21_24, wherein the water-swellable excipient is selected from the group consisting of sodium starch glycolate, crospovidone, croscarmellose, microcrystalline cellulose, starches, and alginic acid.

32. (amended) The process of claim 21_24, wherein the tablet contains about 5 to about 90 % by weight of excipient in the form of a hydrate based on the total weight of the tablet.

33. (amended) The process of claim 21_24, wherein the tablet contains about 0.1 to about 5 % by weight of water-swellable excipient based on the total weight of the tablet.

34. (amended) The process of claim 21_24 wherein the excipient in the form of a hydrate functions as a direct compression filler.

35. (amended) A tablet produced by the process of claim 21_24.